Скачать или смотреть From 21 CFR Part 820 to the QMSR: Pure Global's Deep Dive into the FDA's New Quality System for M...

In this episode of MedTech Global Insights, we explore the monumental shift in the U.S. FDA's approach to quality systems for medical devices. We break down the transition from the long-standing 21 CFR Part 820 regulation to the new Quality Management System Regulation (QMSR), which harmonizes with the global standard ISO 13485. This isn't just a regulatory update; it's a fundamental change in how MedTech companies must approach their global compliance strategy.

We move beyond the theory and dive into the practical realities, discussing the core pillars of a successful quality system, from management responsibility and design controls to the critical role of a robust CAPA system. Learn about the common pitfalls that can lead to costly submission delays and warning letters, and understand why the new QMSR is more than just a copy-and-paste of ISO 13485. This episode provides actionable insights for startups and established enterprises alike on how to turn regulatory compliance into a powerful competitive advantage.

A real-world example: A European startup with a groundbreaking diagnostic device planned a rapid U.S. launch. They believed their ISO 13485 certification made them "FDA ready." However, their submission was put on hold because their Design History File, while compliant with ISO, lacked the specific traceability and risk analysis documentation the FDA expects under its Design Control requirements. This mismatch in expectations cost them an extra year and significant capital to remediate their documentation, allowing a competitor to capture early market share.

Key Takeaways:
Why is the FDA aligning 21 CFR Part 820 with ISO 13485, and what does this mean for your global strategy?
Is your management team just signing documents, or are they truly prepared to defend your quality culture during an FDA inspection?
How can a gap in your Design Controls documentation derail your product launch, even with a revolutionary device?
What is the critical difference between a good CAPA system and a great one that prevents future recalls?
Are you prepared for the specific FDA requirements that go beyond ISO 13485 in the new QMSR?
How does a robust Quality Management System shift from being a regulatory cost center to a strategic business asset?
What are the three most common, yet avoidable, mistakes companies make when facing an FDA quality system inspection?

For questions or support with your global regulatory strategy, contact us at [email protected] or visit https://pureglobal.com/.